Graz, Austria

Hans Miggitsch

This inventor holds 1 USPTO granted patent. Top assignee: Leopold & Co., Chem. Pharm. Fabrik Aktiengesellschaft. Active years: 1991.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 1991

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Hans Miggitsch

Introduction

Hans Miggitsch is a notable inventor based in Graz, Austria. He has made significant contributions to the field of cancer therapy through his innovative research and development. His work focuses on creating effective agents for the destruction of malignant tumors.

Latest Patents

Miggitsch holds a patent for a composition aimed at destroying malignant tumors. This agent contains active substances such as alpha-ketoglutaric acid and 5-hydroxymethylfurfural. The patent describes the agent's versatility, as it can be administered in various forms, including infusion solutions, oral or rectal administration, douches, or ointments.

Career Highlights

Throughout his career, Hans Miggitsch has been associated with Leopold & Co., Chem. Pharm. Fabrik Aktiengesellschaft. His work at this company has allowed him to focus on developing innovative solutions for cancer treatment. His dedication to research has led to advancements in therapeutic agents that can significantly impact patient care.

Collaborations

Miggitsch has collaborated with notable colleagues, including Karl Groke and Josef Polzer. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Hans Miggitsch's contributions to cancer therapy through his patented compositions highlight his commitment to improving treatment options for patients. His innovative spirit and collaborative efforts continue to inspire advancements in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…